IBDEI2S1 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,46616,2)
 ;;=^5008201
 ;;^UTILITY(U,$J,358.3,46617,0)
 ;;=B34.9^^206^2304^89
 ;;^UTILITY(U,$J,358.3,46617,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46617,1,3,0)
 ;;=3^Viral Infection,Unspec
 ;;^UTILITY(U,$J,358.3,46617,1,4,0)
 ;;=4^B34.9
 ;;^UTILITY(U,$J,358.3,46617,2)
 ;;=^5000603
 ;;^UTILITY(U,$J,358.3,46618,0)
 ;;=J12.9^^206^2304^90
 ;;^UTILITY(U,$J,358.3,46618,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46618,1,3,0)
 ;;=3^Viral Pneumonia,Unspec
 ;;^UTILITY(U,$J,358.3,46618,1,4,0)
 ;;=4^J12.9
 ;;^UTILITY(U,$J,358.3,46618,2)
 ;;=^5008169
 ;;^UTILITY(U,$J,358.3,46619,0)
 ;;=J84.114^^206^2305^1
 ;;^UTILITY(U,$J,358.3,46619,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46619,1,3,0)
 ;;=3^AC Interstitial Pneumonitis
 ;;^UTILITY(U,$J,358.3,46619,1,4,0)
 ;;=4^J84.114
 ;;^UTILITY(U,$J,358.3,46619,2)
 ;;=^340536
 ;;^UTILITY(U,$J,358.3,46620,0)
 ;;=J84.09^^206^2305^2
 ;;^UTILITY(U,$J,358.3,46620,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46620,1,3,0)
 ;;=3^Alveolar/Parieto-Alveolar Conditions NEC
 ;;^UTILITY(U,$J,358.3,46620,1,4,0)
 ;;=4^J84.09
 ;;^UTILITY(U,$J,358.3,46620,2)
 ;;=^5008299
 ;;^UTILITY(U,$J,358.3,46621,0)
 ;;=J67.2^^206^2305^3
 ;;^UTILITY(U,$J,358.3,46621,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46621,1,3,0)
 ;;=3^Bird Fancier's Lung
 ;;^UTILITY(U,$J,358.3,46621,1,4,0)
 ;;=4^J67.2
 ;;^UTILITY(U,$J,358.3,46621,2)
 ;;=^14840
 ;;^UTILITY(U,$J,358.3,46622,0)
 ;;=J68.4^^206^2305^5
 ;;^UTILITY(U,$J,358.3,46622,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46622,1,3,0)
 ;;=3^Chr Resp Cond d/t Chemicals/Gases/Fumes/Vapors
 ;;^UTILITY(U,$J,358.3,46622,1,4,0)
 ;;=4^J68.4
 ;;^UTILITY(U,$J,358.3,46622,2)
 ;;=^5008285
 ;;^UTILITY(U,$J,358.3,46623,0)
 ;;=M34.1^^206^2305^4
 ;;^UTILITY(U,$J,358.3,46623,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46623,1,3,0)
 ;;=3^CR(E)ST Syndrome
 ;;^UTILITY(U,$J,358.3,46623,1,4,0)
 ;;=4^M34.1
 ;;^UTILITY(U,$J,358.3,46623,2)
 ;;=^5011779
 ;;^UTILITY(U,$J,358.3,46624,0)
 ;;=J84.116^^206^2305^6
 ;;^UTILITY(U,$J,358.3,46624,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46624,1,3,0)
 ;;=3^Cryptogenic Organizing Pneumonia
 ;;^UTILITY(U,$J,358.3,46624,1,4,0)
 ;;=4^J84.116
 ;;^UTILITY(U,$J,358.3,46624,2)
 ;;=^340539
 ;;^UTILITY(U,$J,358.3,46625,0)
 ;;=J84.117^^206^2305^7
 ;;^UTILITY(U,$J,358.3,46625,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46625,1,3,0)
 ;;=3^Desquamative Interstitial Pneumonia
 ;;^UTILITY(U,$J,358.3,46625,1,4,0)
 ;;=4^J84.117
 ;;^UTILITY(U,$J,358.3,46625,2)
 ;;=^340540
 ;;^UTILITY(U,$J,358.3,46626,0)
 ;;=M32.0^^206^2305^8
 ;;^UTILITY(U,$J,358.3,46626,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46626,1,3,0)
 ;;=3^Drug-Induced Systemic Lupus Erythematosus
 ;;^UTILITY(U,$J,358.3,46626,1,4,0)
 ;;=4^M32.0
 ;;^UTILITY(U,$J,358.3,46626,2)
 ;;=^5011752
 ;;^UTILITY(U,$J,358.3,46627,0)
 ;;=M32.11^^206^2305^9
 ;;^UTILITY(U,$J,358.3,46627,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46627,1,3,0)
 ;;=3^Endocarditis in Systemic Lupus Erythematosus
 ;;^UTILITY(U,$J,358.3,46627,1,4,0)
 ;;=4^M32.11
 ;;^UTILITY(U,$J,358.3,46627,2)
 ;;=^5011754
 ;;^UTILITY(U,$J,358.3,46628,0)
 ;;=J67.0^^206^2305^10
 ;;^UTILITY(U,$J,358.3,46628,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46628,1,3,0)
 ;;=3^Farmer's Lung
 ;;^UTILITY(U,$J,358.3,46628,1,4,0)
 ;;=4^J67.0
 ;;^UTILITY(U,$J,358.3,46628,2)
 ;;=^44962
 ;;^UTILITY(U,$J,358.3,46629,0)
 ;;=M32.14^^206^2305^11
 ;;^UTILITY(U,$J,358.3,46629,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46629,1,3,0)
 ;;=3^Glomerular Disease in Systemic Lupus Erythematosus
 ;;^UTILITY(U,$J,358.3,46629,1,4,0)
 ;;=4^M32.14
